AKBA vs BIIB: Which Stock is Better?
Side-by-side comparison of Akebia Therapeutics Inc and Biogen Inc in 2026
AKBA
Akebia Therapeutics Inc
$1.55
BIIB
Biogen Inc
$180.54
Key Metrics Comparison
| Metric | AKBA | BIIB | Winner |
|---|---|---|---|
| Market Cap | $417.89M | $26.50B | BIIB |
| P/E Ratio | N/A | 20.54 | BIIB |
| EPS (TTM) | $N/A | $8.79 | BIIB |
| Revenue Growth | 0.2% | -0.1% | AKBA |
| Gross Margin | 82.9% | 78.9% | AKBA |
Analyze AKBA
Full quant analysis
Analyze BIIB
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is AKBA or BIIB a better investment?
Comparing AKBA and BIIB: Akebia Therapeutics Inc has a market cap of $417.89M while Biogen Inc has $26.50B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between AKBA and BIIB?
AKBA (Akebia Therapeutics Inc) and BIIB (Biogen Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: AKBA or BIIB?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: AKBA or BIIB?
AKBA has higher revenue growth at 0.2% vs -0.1% for BIIB.
Which company is more profitable: AKBA or BIIB?
Akebia Therapeutics Inc (AKBA) has higher gross margins at 82.9% compared to 78.9% for BIIB.
Which is the larger company: AKBA or BIIB?
Biogen Inc (BIIB) is larger with a market cap of $26.50B compared to $417.89M for AKBA.
Should I buy AKBA or BIIB in 2026?
Both AKBA and BIIB have investment merit. AKBA trades at $1.55 while BIIB trades at $180.54. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between AKBA and BIIB stock?
Key differences: Market Cap ($417.89M vs $26.50B), P/E Ratio (N/A vs 20.5x), Revenue Growth (0.2% vs -0.1%), Gross Margin (82.9% vs 78.9%).